EGFR inhibitor AZD9291 and necitumumab in treating patients with EGFR-positive stage IV or recurrent non-small cell lung cancer (NSCLC) who have progressed on a previous EGFR tyrosine kinase inhibitor (TKI). This evidence concerns the gene EGFR and non-small cell lung carcinoma.